Abstract
As for other peptides such as bradykinin, neurokinins and angiotensins, peptide antagonists for endothelin-1 (ET-1) have been early on developed towards the pharmacological characterization of both ETA and ETB receptors. Interestingly, unlike the previously mentioned three peptides, receptors for ET-1 were cloned and purified prior to the report of ETA and ETB receptor antagonists such as BQ-123 and BQ-788. The availability of such pharmacological tools and the use of molecular approaches have certainly fast-tracked the development of non-peptide ET receptor antagonists for clinical applications. Albeit rapid degradation by gastric enzymes and short halflife in plasma of peptide receptor antagonists limit their use in clinical settings, those molecules have been of importance in the identification of mediators and modulators of ET-1 induced properties in vitro and in vivo, as described further in this review. Peptide antagonists acting selectively or, with equivalent affinities against ETA and ETB receptors were reported prior to the advent of clinically relevant non-peptide blockers such as Bosentan. Confounding mechanisms involving, for example, the endogenous modulators nitric oxide and prostacyclin as well as allosteric interactions between ET receptor types, have also been clarified with the use of peptide antagonists for endothelins. Finally, peptide antagonists were also used to identify the precise pharmacology of ET-1 precursors such as big-endothelin-1 and ET-1 (1-31).
The present review will thus attempt to summarize the knowledge to date and future perspectives related to use of peptide antagonists targeting endothelin receptors in physiological and pathological settings.
Keywords: Endothelin-1, antagonists, ETA and ETB receptors, Streptomyces misakiensis, amino acid isoforms, disulfide bonds, pulmonary hypertension, sulfamethoxazole, subarachnoid hemorrhage, Salicylic acid, Neurogenesis, Hippocampus, Neuroblast, Rostral migratory stream, brain tumor stem cell, NG2, Ependyma, Stem cell, dentate gyrus, subgranular zone, cytokine, PSA-NCAM, Ki67, Interleukin
Current Pharmaceutical Design
Title: Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Volume: 17 Issue: 25
Author(s): Martin Houde, Julie Labonte and Pedro D'Orleans-Juste
Affiliation:
Keywords: Endothelin-1, antagonists, ETA and ETB receptors, Streptomyces misakiensis, amino acid isoforms, disulfide bonds, pulmonary hypertension, sulfamethoxazole, subarachnoid hemorrhage, Salicylic acid, Neurogenesis, Hippocampus, Neuroblast, Rostral migratory stream, brain tumor stem cell, NG2, Ependyma, Stem cell, dentate gyrus, subgranular zone, cytokine, PSA-NCAM, Ki67, Interleukin
Abstract: As for other peptides such as bradykinin, neurokinins and angiotensins, peptide antagonists for endothelin-1 (ET-1) have been early on developed towards the pharmacological characterization of both ETA and ETB receptors. Interestingly, unlike the previously mentioned three peptides, receptors for ET-1 were cloned and purified prior to the report of ETA and ETB receptor antagonists such as BQ-123 and BQ-788. The availability of such pharmacological tools and the use of molecular approaches have certainly fast-tracked the development of non-peptide ET receptor antagonists for clinical applications. Albeit rapid degradation by gastric enzymes and short halflife in plasma of peptide receptor antagonists limit their use in clinical settings, those molecules have been of importance in the identification of mediators and modulators of ET-1 induced properties in vitro and in vivo, as described further in this review. Peptide antagonists acting selectively or, with equivalent affinities against ETA and ETB receptors were reported prior to the advent of clinically relevant non-peptide blockers such as Bosentan. Confounding mechanisms involving, for example, the endogenous modulators nitric oxide and prostacyclin as well as allosteric interactions between ET receptor types, have also been clarified with the use of peptide antagonists for endothelins. Finally, peptide antagonists were also used to identify the precise pharmacology of ET-1 precursors such as big-endothelin-1 and ET-1 (1-31).
The present review will thus attempt to summarize the knowledge to date and future perspectives related to use of peptide antagonists targeting endothelin receptors in physiological and pathological settings.
Export Options
About this article
Cite this article as:
Houde Martin, Labonte Julie and D'Orleans-Juste Pedro, Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology, Current Pharmaceutical Design 2011; 17 (25) . https://dx.doi.org/10.2174/138161211797416101
DOI https://dx.doi.org/10.2174/138161211797416101 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Effects of Oral Tofisopam on Plasma Concentration and Urinary Excretion of Uric Acid and Oxypurinol “Preliminary Communication”
Current Clinical Pharmacology The Clinical Development of γ-Hydroxybutyrate (GHB)
Current Drug Safety Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Basal Septal Hypertrophy
Current Cardiology Reviews A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Prediabetic Dysglycemia: Call for Action
Current Diabetes Reviews Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery Cell-free Nucleic Acids as a Non-Invasive Route for Investigating Atherosclerosis
Current Pharmaceutical Design Dietary Adherence, Self-Efficacy, and Health Behavior Change of WASHOKU-Modified DASH Diet: A Sub-analysis of the DASH-JUMP Study
Current Hypertension Reviews A Review of Patents on Therapeutic Potential and Delivery of Hydroge n Sulfide
Recent Patents on Drug Delivery & Formulation Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Foreword [ Current Vascular Pharmacology is 10 Years Old! ]
Current Vascular Pharmacology Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design